OverviewSuggest Edit

Verastem is a biopharmaceutical company that is engaged in the discovery and development of drugs to improve outcomes for patients with cancer. The Company provides an oral inhibitor of phosphoinositide 3-kinase and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

TypePublic
Founded2010
HQNeedham, US
Websiteverastem.com
Employee Ratings4.6

Latest Updates

Employees (est.) (Dec 2018)169(+145%)
Revenue (FY, 2019)$17.5 M(-34%)
Share Price (Nov 2020)$1.5
Cybersecurity ratingAMore

Key People/Management at Verastem

Brian Stuglik

Brian Stuglik

Chief Executive Officer, Director
Michael Kauffman

Michael Kauffman

Lead Director
Dan Paterson

Dan Paterson

President and Chief Operating Officer
Rob Gagnon

Rob Gagnon

Chief Business and Financial Officer
Jonathan Pachter

Jonathan Pachter

Chief Scientific Officer
Cathy Carew

Cathy Carew

Chief People and Organizational Strategy Officer
Show more

Verastem Office Locations

Verastem has offices in Needham and Walsrode
Needham, US (HQ)
117 Kendrick St
Walsrode, DE
Lange Str. 70
Show all (2)

Verastem Financials and Metrics

Verastem Revenue

Verastem's revenue was reported to be $17.46 m in FY, 2019
USD

Revenue (Q2, 2020)

4.3m

Net income (Q2, 2020)

(23.0m)

EBIT (Q2, 2020)

(21.3m)

Market capitalization (20-Nov-2020)

249.6m

Closing stock price (20-Nov-2020)

1.5

Cash (30-Jun-2020)

125.3m

EV

152.9m
Verastem's current market capitalization is $249.6 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

26.7m17.5m

Cost of goods sold

165.0k

Gross profit

26.6m

Gross profit Margin, %

99%
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

10.0m15.5m1.7m3.1m9.0m5.1m4.3m

Cost of goods sold

49.0k158.0k

Gross profit

15.5m1.5m

Gross profit Margin, %

100%91%
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

10.1m18.9m33.9m24.9m32.3m82.2m129.9m43.5m

Accounts Receivable

306.0k2.5m

Prepaid Expenses

506.0k557.0k2.6m585.0k1.1m3.0m3.8m

Inventories

327.0k3.1m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

25.5m15.8m11.1m28.2m13.9m22.6m13.2m22.4m20.6m30.1m35.2m19.8m15.1m39.6m37.3m28.2m27.6m51.3m64.2m168.7m130.7m91.5m113.1m103.3m135.1m125.3m

Accounts Receivable

10.6m558.0k1.4m2.2m3.3m1.5m

Prepaid Expenses

490.0k509.0k429.0k986.0k841.0k1.1m857.0k877.0k1.0m2.8m651.0k714.0k1.0m667.0k431.0k1.4m1.8m940.0k1.8m1.7m2.4m4.1m3.4m4.0m5.9m6.6m

Inventories

131.0k306.0k294.0k478.0k4.4m6.3m
USDQ1, 2012

Financial Leverage

1 x
Show all financial metrics

Verastem Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Verastem Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Verastem Online and Social Media Presence

Embed Graph

Verastem News and Updates

Thinking about buying stock in Scholar Rock Holding, Electrameccanica Vehicles, Verastem, Oncolytics Biotech, or Cisco Systems?

NEW YORK, Oct. 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRRK, SOLO, VSTM, ONCY, and CSCO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Steven Cohen Renews His Interest In Verastem

Billionaire investor Steven Cohen (Trades, Portfolio), head of Point72 Asset Management, disclosed earlier this week his firm established a new 14.91% stake in Verastem Inc. (NASDAQ:VSTM).

Brainstorm Health: Health Data Breaches, NIH Precision Medicine Funding, Verastem Approval

Brainstorm Health Daily: September 25, 2018
Show more

Verastem Blogs

Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Previous Data from Investigator-Initiated Phase 1/2 Trial Show Encouraging Response Rates, Durability and a Favorable Safety Profile Phase 2 Adaptive Trial Design to Evaluate VS-6766 Alone and in Combination with Defactinib Verastem to Seek FDA Accelerated Approval, Pending Trial Outcome BOSTON

Verastem Oncology Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress

Announced Positive Updated Data from Ongoing Investigator-Initiated Phase 1/2 FRAME Study Evaluating VS-6766 and Defactinib Combination in Patients with Low-Grade Serous Ovarian Cancer On Track to Commence Company-Sponsored Phase 2 Registration-Directed Trials by Year-End 2020 in Both Low-Grade

Verastem Oncology Announces New Data Published in The Lancet Oncology Supports Potential of VS-6766 as Treatment for RAS Mutant Tumors

Investigator-Initiated Phase 1 Study is First to Evaluate a Dual RAF/MEK Inhibitor Using Innovative Intermittent Dosing Schedules in Patients Harboring RAS/RAF Pathway Mutations Study Finds VS-6766 Regimen is Tolerable and Shows Antitumor Activity in Recommended Phase 2 Single Agent Dose Phase 2

Verastem Oncology Announces Closing of COPIKTRA® (duvelisib) Sale to Secura Bio

Verastem Now Focused on Development of VS-6766 and Defactinib Combination in Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer Registration-Directed Clinical Trials in LGSOC and KRAS Mutant NSCLC Expected to Commence by Year End 2020 BOSTON --(BUSINESS WIRE)--Sep.

Verastem Oncology Announces Presentation of Updated Phase 1/2 FRAME Study Data at the 2nd Annual RAS-Targeted Drug Development Summit

Preliminary Data on VS-6766 and Defactinib Combination Continues to Show Encouraging Response Rates, Durability and a Favorable Safety Profile in KRAS Mutant Low-Grade Serous Ovarian Cancer in Investigator-Initiated Trial New Preclinical Data Demonstrating Synergy and Tumor Regression with G12C

Verastem Oncology Announces Investor Conference Call to Discuss Updated Clinical Data in Low-Grade Serous Ovarian Cancer from Phase 1/2 FRAME Study

Verastem Oncology Announces Investor Conference Call to Discuss Updated Clinical Data in Low-Grade Serous Ovarian Cancer from Phase 1/2 FRAME Study Content Import Mon, 09/14/2020 - 07:01 Verastem Oncology Announces Investor Conference Call to Discuss Updated Clinical Data in Low-Grade Sero…
Show more

Verastem Frequently Asked Questions

  • When was Verastem founded?

    Verastem was founded in 2010.

  • Who are Verastem key executives?

    Verastem's key executives are Brian Stuglik, Michael Kauffman and Dan Paterson.

  • How many employees does Verastem have?

    Verastem has 169 employees.

  • What is Verastem revenue?

    Latest Verastem annual revenue is $17.5 m.

  • What is Verastem revenue per employee?

    Latest Verastem revenue per employee is $103.3 k.

  • Who are Verastem competitors?

    Competitors of Verastem include Del Mar Pharmaceuticals, Ablynx and Genocea Biosciences.

  • Where is Verastem headquarters?

    Verastem headquarters is located at 117 Kendrick St, Needham.

  • Where are Verastem offices?

    Verastem has offices in Needham and Walsrode.

  • How many offices does Verastem have?

    Verastem has 2 offices.